Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
If symptoms escalate, pause titration and contact your clinician for tailored adjustment
23(9): p
[1] [3] Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist with similar clinical effects
Key Findings 1 Tirzepatide reduced major kidney events by 23% vs dulaglutide Events: 6.0% vs 7.6% HR 0.77 (95% CI 0.680.88), p=0.0002 The risk of the primary composite kidney outcomewas 23% lower with tirzepatide than with dulaglutide. 2 Benefits were consistent across CKD risk categories Lowtomoderate risk CKD: HR 0.70 Highrisk CKD: HR 0.79 3 Mechanistic drivers differed by CKD stage Lowtomoderate CKD: Less newonset macroalbuminuria Highrisk CKD: Slower eGFR decline This was primarily driven by a lower rate of new-onset persistent macroalbuminuria and a lower rate of eGFR decline. 4 eGFR decline was significantly slower with tirzepatide Overall difference: +0.29 mL/min/1.73 m per year Highrisk CKD: +0.93 mL/min/1.73 m per year 5 Albuminuria improved more with tirzepatide At 36 months, UACR reductions were greater across CKD categories
